Treatment for acute myeloid leukemia or lymphoma
AssigneeUniversity Health Network
InventorsMark R. Bray, Jacqueline M. Mason, Xin Wei, Gordon Duncan
Life of this patent
Estimating the term…
Abstract
The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma by administration of Compound (I), or a pharmaceutically acceptable salt thereof.
Claims31
A method of treating a subject with acute myeloid leukemia, comprising administering an effective amount of Compound (I):
- or a pharmaceutically acceptable salt thereof, wherein the acute myeloid leukemia
- is FLT3 mutated acute myeloid leukemia;
- is acute myeloid leukemia with MLL-AF9 translocation;
- overexpresses wild-type FLT3;
- overexpresses transforming growth factor-b activated kinase 1 (TAK1);
- is TAK1 mutated;
- or
- is acute myeloid leukemia with increased TAK1 signaling.
A method of treating a subject with acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, comprising administering an effective amount of Compound (I):
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.